Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §112 only | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.3% |
| DUNN, LINDSAY MICHELLE | 1 | 100.0% | +0.0% |
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| SHUPE, ELIZABETH A | 1 | 63.3% | +49.1% |
| GAMETT, DANIEL C | 1 | 67.6% | +28.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554426 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HABTE, KAHSAY | 29d overdue |
| 18272539 | ANTI-HUMAN CD22 MONOCLONAL ANTIBODIES AND USE THEREOF | DUNN, LINDSAY MICHELLE | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18265150 | ANTI-CD22 NANO ANTIBODY AND USE THEREOF | GAMETT, DANIEL C | 9d |
| 18266125 | ANTI-EGFR NANOBODY AND USE THEREOF | SHUPE, ELIZABETH A | 19d |
| 18267561 | HER2 ANTIBODY AND APPLICATION THEREOF | WEN, SHARON X | 57d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554426 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | 29d overdue | Pending | Oct 06, 2023 |
| 18272539 | ANTI-HUMAN CD22 MONOCLONAL ANTIBODIES AND USE THEREOF | DUNN, LINDSAY MICHELLE | 1644 | §103 | Non-Final OA | 40d | Pending | Jul 14, 2023 |
| 18267561 | HER2 ANTIBODY AND APPLICATION THEREOF | WEN, SHARON X | 1641 | §103 | Non-Final OA | 57d | Pending | Jun 15, 2023 |
| 18266125 | ANTI-EGFR NANOBODY AND USE THEREOF | SHUPE, ELIZABETH A | 1643 | §103 | Non-Final OA | 19d | Pending | Jun 08, 2023 |
| 18265150 | ANTI-CD22 NANO ANTIBODY AND USE THEREOF | GAMETT, DANIEL C | 1647 | §112 | Non-Final OA | 9d | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial